RxDoctor Payments Data

Danielle Ortega, DO

Family Medicine · Atlanta, GANPI 1619408051

Payments from drug & device makers

$1,734in general payments, 2019–2025

Across 66 payments — averaging $26.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Zimmer Biomet$373
  • Lilly USA, LLC$301
  • AstraZeneca$241
  • Novo Nordisk$194
  • Astellas Pharma US Inc$106
  • Exact Sciences$94
  • plus $425 from 9 others

What the payments were for

  • Food & beverage$1,734100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,734 in reported general payments places this provider in the 65th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$15,328
Medicare patients
47
Services billed
203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide62$56,477
MounjaroTirzepatide47$49,598
TrulicityDulaglutide23$22,487
XareltoRivaroxaban12$19,280
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$2,331
Albuterol Sulfate HfaAlbuterol Sulfate49$1,428
Diclofenac Sodium61$1,385
Atorvastatin Calcium87$747
Chlorthalidone33$659
Gabapentin44$521
Amlodipine Besylate86$459
Fluticasone Propionate45$420
Tizanidine Hcl13$380
Famotidine17$337
Hydralazine Hcl12$270

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$301$72,08570 claims
Novo NordiskOzempic$194$56,47762 claims
Johnson & JohnsonXarelto$19$19,28012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →